Beijing SL Pharmaceutical Co Ltd Total Liabilities
Beijing SL Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has total liabilities worth CN¥735.46 Million CNY (≈ $107.62 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002038 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Beijing SL Pharmaceutical Co Ltd (2001–2025)
Total liabilities of Beijing SL Pharmaceutical Co Ltd from 2001 to 2025. This chart illustrates how Beijing SL Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Beijing SL Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Beijing SL Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinostone Guangdong Co Ltd
SHE:001212
|
China | CN¥308.95 Million |
|
Shanghai Baosteel Packaging
SHG:601968
|
China | CN¥5.43 Billion |
|
Zhejiang Damon Technology Co Ltd
SHG:688360
|
China | CN¥2.09 Billion |
|
Fujian MinDong Electric Power Co Ltd
SHE:000993
|
China | CN¥981.01 Million |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
China | CN¥885.87 Million |
|
J.Pond Precision Technology Co. Ltd. A
SHE:301326
|
China | CN¥1.24 Billion |
|
Shanghai Diesel Engine Co Ltd A
SHG:600841
|
China | CN¥10.14 Billion |
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
China | CN¥537.86 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Beijing SL Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002038 current and non-current assets.
Liquidity & Leverage Metrics
Beijing SL Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Beijing SL Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing SL Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing SL Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Beijing SL Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥883.49 Million ≈ $129.28 Million |
+121.78% |
| 2024-12-31 | CN¥398.37 Million ≈ $58.29 Million |
-14.83% |
| 2023-12-31 | CN¥467.72 Million ≈ $68.44 Million |
+17.93% |
| 2022-12-31 | CN¥396.60 Million ≈ $58.04 Million |
-8.67% |
| 2021-12-31 | CN¥434.23 Million ≈ $63.54 Million |
+5.89% |
| 2020-12-31 | CN¥410.09 Million ≈ $60.01 Million |
+1.57% |
| 2019-12-31 | CN¥403.76 Million ≈ $59.08 Million |
-14.05% |
| 2018-12-31 | CN¥469.73 Million ≈ $68.74 Million |
+64.43% |
| 2017-12-31 | CN¥285.67 Million ≈ $41.80 Million |
+88.95% |
| 2016-12-31 | CN¥151.19 Million ≈ $22.12 Million |
+1.88% |
| 2015-12-31 | CN¥148.40 Million ≈ $21.72 Million |
+7.60% |
| 2014-12-31 | CN¥137.92 Million ≈ $20.18 Million |
+12.05% |
| 2013-12-31 | CN¥123.09 Million ≈ $18.01 Million |
+17.04% |
| 2012-12-31 | CN¥105.17 Million ≈ $15.39 Million |
+108.19% |
| 2011-12-31 | CN¥50.52 Million ≈ $7.39 Million |
+35.72% |
| 2010-12-31 | CN¥37.22 Million ≈ $5.45 Million |
+1.28% |
| 2009-12-31 | CN¥36.75 Million ≈ $5.38 Million |
+41.86% |
| 2008-12-31 | CN¥25.91 Million ≈ $3.79 Million |
-25.36% |
| 2007-12-31 | CN¥34.71 Million ≈ $5.08 Million |
-1.98% |
| 2006-12-31 | CN¥35.41 Million ≈ $5.18 Million |
+51.19% |
| 2005-12-31 | CN¥23.42 Million ≈ $3.43 Million |
-17.47% |
| 2004-12-31 | CN¥28.38 Million ≈ $4.15 Million |
-22.84% |
| 2003-12-31 | CN¥36.78 Million ≈ $5.38 Million |
+113.50% |
| 2002-12-31 | CN¥17.23 Million ≈ $2.52 Million |
+58.96% |
| 2001-12-31 | CN¥10.84 Million ≈ $1.59 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more